Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma Specialities, a subsidiary of the company. There is no impact on the existing supplies to the US market.
The warning letter comes subsequent to receiving the Official Action Indicated (OAI) status from USFDA earlier in May 2024.

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025
4 mins read . Sep 5, 2025

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025
3 mins read . Aug 20, 2025

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025
8 mins read . Aug 18, 2025

Explore our products
Unlimited Trading starting at ₹249 ₹0
Open Trading Account
Recent Article
- •
- •
- •
- •